

*Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction where such distribution of this press release would be subject to legal restrictions. This press release does not constitute an offer of any securities of Karo Pharma AB. See also section "IMPORTANT INFORMATION" below.*

**KARO**  
**PUBLISHES**

**KARO**  
**PHARMA**

**PHARMA**  
**PROSPECTUS**

**AND INTENTION TO ISSUE BOND**

STOCKHOLM, 11 May 2018

Karo Pharma AB's ("Karo Pharma") prospectus regarding the fully guaranteed rights issue has today been approved and registered by the Swedish Financial Supervisory Authority. The prospectus is available on Karo Pharma's website [www.karopharma.se](http://www.karopharma.se), on SEB's website [www.sebgroup.com/prospectuses](http://www.sebgroup.com/prospectuses) and on Swedbank's website [www.swedbank.se/prospekt](http://www.swedbank.se/prospekt).

The prospectus sets forth Karo Pharma's intention to issue bond loans in 2018 corresponding to SEK 1,000 million after deductions for issue costs. The proceeds will be used to amortise a short-term loan of SEK 1,000 million.

**IMPORTANT INFORMATION ON LEI AND NID**

As a result of MiFID II/MIFIR, all legal entities and natural persons need a LEI (Legal Entity Identifier) number or NID (National ID or National Client Identifier) code respectively in order to participate in financial transactions from 3 January 2018. A LEI number is a global identification code for legal entities and a NID number is a global identification code for natural persons.

Investors wishing to apply for subscription without rights needs to obtain a LEI in the case of legal entities or find out their NID in the case of natural persons.

**Swedbank has the right to disregard the application, without any liability towards the applicant, if a LEI or a NID number (as applicable) is not provided upon application.**

A legal entity in need of obtaining a LEI can turn to [www.gleif.org/en/about-lei/how-to-get-an-lei-find-lei-issuing-organizations](http://www.gleif.org/en/about-lei/how-to-get-an-lei-find-lei-issuing-organizations) and any one of the LEI suppliers listed there in order to obtain a LEI, and should do so in good time before applying to subscribe without rights, as there is an administrative turnaround time with the LEI supplier.

**Financial and legal advisors**

SEB Corporate Finance and Swedbank Corporate Finance are Joint Global Coordinators and Hamilton Advokatbyrå is legal advisor to Karo Pharma in relation to the rights issue.

**FOR ADDITIONAL INFORMATION, PLEASE CONTACT:**

Peter Blom, CEO, +46 (0) 70-655 56 98 or [peter.blom@karopharma.se](mailto:peter.blom@karopharma.se)

*This information is information that Karo Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the above contact person's agency, at 09:30 CEST on 11 May 2018. This press release is also available at [www.karopharma.se](http://www.karopharma.se) and [www.newsroom.cision.com](http://www.newsroom.cision.com).*

**ABOUT KARO PHARMA**

Karo Pharma is a Specialty Pharmaceutical company, which develops and markets products for pharmacies as well as directly to the healthcare sector. Karo Pharma is listed on Nasdaq Stockholm, Mid Cap.

**IMPORTANT INFORMATION**

The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in Karo Pharma AB. Any invitation to the persons entitled to subscribe for shares in Karo Pharma AB is made solely through the prospectus which Karo Pharma AB publishes on 11 May 2018.

This press release may not be released, published or distributed, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, Singapore, the United States or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to what follows from Swedish law. Nor may the information in this press release be forwarded, reproduced or disclosed in a manner that contravenes such restrictions or would entail such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.

No subscription rights, BTAs (interim shares) or new shares have or will be registered under the United States Securities Act of 1933 ("Securities Act") or securities legislation in any state or other jurisdiction in the United States and may not be offered, subscribed, used, pledged, sold, resold, allotted, delivered or transferred, directly or indirectly, into or within the United States, other than pursuant to an exemption from, or in a transaction that is subject to, the registration requirements of the Securities Act. The offering is not aimed for individuals with

residence in Australia, Hong Kong, Switzerland, and Singapore nor in any other jurisdiction where participation would require additional prospectus, registration or other arrangements aside of the Swedish law system.